Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07.Submission of Matters to a Vote of Security Holders.

Inotek Pharmaceuticals Corporation (the Company) held its Annual
Meeting of Shareholders (the Annual Meeting) on June20, 2017. As
of April21, 2017, the record date for the Annual Meeting, there
were 26,986,318 outstanding shares of the Companys common stock.
The Companys shareholders voted on the following matters, which
are described in detail in the Companys Definitive Proxy
Statement filed with the U.S. Securities and Exchange Commission
(SEC) on April26, 2017: (i)to elect Timothy Barberich, Paul G.
Howes and Patrick Machado as Class III directors of the Company,
each to serve for a three-year term expiring at the Companys
annual meeting of shareholders in 2020 and until their successors
have been duly elected and qualified, subject to their earlier
resignation or removal (Proposal 1) and (ii)to ratify the
appointment of RSM US LLP as the Companys independent registered
public accounting firm for the fiscal year ending December31,
2017 (Proposal 2).

The Companys shareholders approved the Class III director
nominees recommended for election in Proposal 1 at the Annual
Meeting. The Companys shareholders voted for Class III directors
as follows:

The Companys shareholders approved Proposal 2. The votes cast at
the Annual Meeting were as follows:

No other matters were submitted to or voted on by the Companys
shareholders at the Annual Meeting.

***

About Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)

Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye’s trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.